These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 37728121)

  • 21. Fidaxomicin inhibits Clostridium difficile toxin A-mediated enteritis in the mouse ileum.
    Koon HW; Ho S; Hing TC; Cheng M; Chen X; Ichikawa Y; Kelly CP; Pothoulakis C
    Antimicrob Agents Chemother; 2014 Aug; 58(8):4642-50. PubMed ID: 24890583
    [TBL] [Abstract][Full Text] [Related]  

  • 22.
    Sun Q; Liao X; Wang C; Jiang G; Yang J; Zhao J; Huang H; Wang G; Li H
    J Med Microbiol; 2022 Jun; 71(6):. PubMed ID: 35708979
    [No Abstract]   [Full Text] [Related]  

  • 23. Antibiotic treatment for Clostridium difficile-associated diarrhoea in adults.
    Nelson RL; Suda KJ; Evans CT
    Cochrane Database Syst Rev; 2017 Mar; 3(3):CD004610. PubMed ID: 28257555
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effects of inoculum, pH, and cations on the in vitro activity of fidaxomicin (OPT-80, PAR-101) against Clostridium difficile.
    Babakhani F; Seddon J; Robert N; Shue YK; Sears P
    Antimicrob Agents Chemother; 2010 Jun; 54(6):2674-6. PubMed ID: 20308366
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Fidaxomicin for the treatment of
    Skinner AM; Scardina T; Kociolek LK
    Future Microbiol; 2020 Jul; 15(11):967-979. PubMed ID: 32715754
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Formal Single Atom Editing of the Glycosylated Natural Product Fidaxomicin Improves Acid Stability and Retains Antibiotic Activity.
    Ferrara I; Chesnokov GA; Dittmann S; Blacque O; Sievers S; Gademann K
    JACS Au; 2024 Jun; 4(6):2267-2280. PubMed ID: 38938792
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Antibacterials Developed to Target a Single Organism: Mechanisms and Frequencies of Reduced Susceptibility to the Novel Anti-Clostridium difficile Compounds Fidaxomicin and LFF571.
    Leeds JA
    Cold Spring Harb Perspect Med; 2016 Feb; 6(2):a025445. PubMed ID: 26834162
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Visualization of fidaxomicin association with the exosporium layer of Clostridioides difficile spores.
    Bassères E; Endres BT; Montes-Bravo N; Pérez-Soto N; Rashid T; Lancaster C; Begum K; Alam MJ; Paredes-Sabja D; Garey KW
    Anaerobe; 2021 Jun; 69():102352. PubMed ID: 33640461
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The use of fidaxomicin for treatment of relapsed Clostridium difficile infections in patients with cancer.
    Esmaily-Fard A; Tverdek FP; Crowther DM; Ghantoji SS; Adachi JA; Chemaly RF
    Pharmacotherapy; 2014 Nov; 34(11):1220-5. PubMed ID: 25164587
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Inhibitory effect of fidaxomicin on biofilm formation in Clostridioides difficile.
    Hamada M; Yamaguchi T; Ishii Y; Chono K; Tateda K
    J Infect Chemother; 2020 Jul; 26(7):685-692. PubMed ID: 32224190
    [TBL] [Abstract][Full Text] [Related]  

  • 31. In vitro selection, via serial passage, of Clostridium difficile mutants with reduced susceptibility to fidaxomicin or vancomycin.
    Leeds JA; Sachdeva M; Mullin S; Barnes SW; Ruzin A
    J Antimicrob Chemother; 2014 Jan; 69(1):41-4. PubMed ID: 23887866
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Fidaxomicin: a novel macrolide antibiotic for Clostridium difficile infection.
    Chahine EB; Sucher AJ; Mantei K
    Consult Pharm; 2014 Sep; 29(9):614-24. PubMed ID: 25203410
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Investigations of the mode of action and resistance development of cadazolid, a new antibiotic for treatment of Clostridium difficile infections.
    Locher HH; Caspers P; Bruyère T; Schroeder S; Pfaff P; Knezevic A; Keck W; Ritz D
    Antimicrob Agents Chemother; 2014; 58(2):901-8. PubMed ID: 24277035
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Investigation of the MICs of fidaxomicin and other antibiotics against Hungarian Clostridium difficile isolates.
    Eitel Z; Terhes G; Sóki J; Nagy E; Urbán E
    Anaerobe; 2015 Feb; 31():47-9. PubMed ID: 25139122
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Fidaxomicin and OP-1118 Inhibit Clostridium difficile Toxin A- and B-Mediated Inflammatory Responses via Inhibition of NF-κB Activity.
    Koon HW; Wang J; Mussatto CC; Ortiz C; Lee EC; Tran DH; Chen X; Kelly CP; Pothoulakis C
    Antimicrob Agents Chemother; 2018 Jan; 62(1):. PubMed ID: 29038278
    [No Abstract]   [Full Text] [Related]  

  • 36. A prospective, observational study of fidaxomicin use for
    Guery B; Berger P; Gauzit R; Gourdon M; Barbut F; ; Dafne Study Group ; Bémer P; Bessède E; Camou F; Cattoir V; Couzigou C; Descamps D; Dinh A; Laurans C; Lavigne JP; Lechiche C; Leflon-Guibout V; Le Monnier A; Levast M; Mootien JY; N'Guyen Y; Piroth L; Prazuck T; Rogeaux O; Roux AL; Vachée A; Vernet Garnier V; Wallet F
    J Int Med Res; 2021 Jun; 49(6):3000605211021278. PubMed ID: 34162264
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Killing kinetics of fidaxomicin and its major metabolite, OP-1118, against Clostridium difficile.
    Babakhani F; Gomez A; Robert N; Sears P
    J Med Microbiol; 2011 Aug; 60(Pt 8):1213-1217. PubMed ID: 21349983
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparative susceptibilities to fidaxomicin (OPT-80) of isolates collected at baseline, recurrence, and failure from patients in two phase III trials of fidaxomicin against Clostridium difficile infection.
    Goldstein EJ; Citron DM; Sears P; Babakhani F; Sambol SP; Gerding DN
    Antimicrob Agents Chemother; 2011 Nov; 55(11):5194-9. PubMed ID: 21844318
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Antimicrobial profile and clinical evidence of fidaxomicin (Dafclir
    Takeda S; Miki T
    Nihon Yakurigaku Zasshi; 2019; 154(4):217-229. PubMed ID: 31597902
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Inhibition of selenoprotein synthesis is not the mechanism by which auranofin inhibits growth of Clostridioides difficile.
    Johnstone MA; Holman MA; Self WT
    Sci Rep; 2023 Sep; 13(1):14733. PubMed ID: 37679389
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.